Question 1

What is ODM-212?

Accepted Answer

ODM-212 is a Other.

Question 2

How often does ODM-212 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was ODM-212 first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was ODM-212 last mentioned in news?

Accepted Answer

Last active on May 30, 2026.

Question 5

What is ODM-212's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is ODM-212 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving ODM-212?

Accepted Answer

Orion Pharma Presents ODM-212 Trial Data (May 21, 2026, 6 articles).

Question 8

How did the "Orion Pharma Presents ODM-212 Trial Data" event impact ODM-212?

Accepted Answer

ODM-212 is an investigational oral small-molecule pan-TEAD inhibitor developed by Orion, showing early efficacy in treating advanced solid tumors, particularly mesothelioma and EHE.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.